Blog

Naveen Pemmaraju: Azacitidine, Venetoclax and Magrolimab in Newly Diagnosed and Relapsed AML

Naveen Pemmaraju/mdanderson.org

Apr 29, 2025, 09:33

Naveen Pemmaraju: Azacitidine, Venetoclax and Magrolimab in Newly Diagnosed and Relapsed AML

Naveen Pemmaraju, Professor and Director of BPDCN Program at the Department of Leukemia at the University of Texas MD Anderson Cancer Center, shared an article by Naval Daver, et al. on X:

“Azacitidine, Venetoclax and Magrolimab in Newly Diagnosed and Relapsed Refractory Acute Myeloid Leukemia: Phase 1b/2 Study and Correlative Analysis | Led by Naval Daver and Hussein Abbas.”

Azacitidine, Venetoclax and Magrolimab in Newly Diagnosed and Relapsed Refractory Acute Myeloid Leukemia: Phase 1b/2 Study and Correlative Analysis.

Journal: Clinical Cancer Research.

Authors: Naval Daver, et al.

Naveen Pemmaraju: Azacitidine, Venetoclax and Magrolimab in Newly Diagnosed and Relapsed AML

More posts featuring Naveen Pemmaraju.

AML azacitidine BPDCN Program cancer fight against cancer Global fight against cancer Hussein Abbas magrolimab MD Anderson Cancer Center Naval Daver Naveen Pemmaraju OncoDaily Oncology University of Texas venetoclax

Oncologist Near Me – Razelle Kurzrock: Revolutionizing Cancer Treatment Through Precision Medicine

Smoking and Bladder Cancer: What You Need to Know to Protect Yourself

Cervical Cancer Screening: Who Needs a Pap Smear or HPV Test and When?

Clinical Trials in Cancer Care: What They Are, How to Join, and What to Expect

Linda Evangelista and Breast Cancer: How She Went Against, How She Survived, and More